A new nonhydrolyzable reactive cGMP analogue, (Rp)-guanosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate, which targets the cGMP binding site of human platelet PDE3A |
| |
Authors: | Hung Su H Liu Andy H Pixley Robin A Francis Penelope Williams LaTeeka D Matsko Christopher M Barnes Karine D Sivendran Sharmila Colman Roberta F Colman Robert W |
| |
Affiliation: | aThe Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad Street, OMS 418, Philadelphia, PA 19140, USA;bDepartment of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716, USA |
| |
Abstract: | The amino acids involved in substrate (cAMP) binding to human platelet cGMP-inhibited cAMP phosphodiesterase (PDE3A) are identified. Less is known about the inhibitor (cGMP) binding site. We have now synthesized a nonhydrolyzable reactive cGMP analog, Rp-guanosine-3′,5′-cyclic-S-(4-bromo-2, 3-dioxobutyl)monophosphorothioate (Rp-cGMPS-BDB). Rp-cGMPS-BDB irreversibly inactivates PDE3A (KI = 43.4 ± 7.2 μM and kcart = 0.007 ± 0.0006 min−1). The effectiveness of protectants in decreasing the rate of inactivation by Rp-cGMPS-BDB is: Rp-cGMPS (Kd = 72 μM) > Sp-cGMPS (124), Sp-cAMPS (182) > GMP (1517), Rp-cAMPS (3762), AMP (4370 μM). NAD+, neither a substrate nor an inhibitor of PDE3A, does not protect. Nonhydrolyzable cGMP analogs exhibit greater affinity than the cAMP analogs. These results indicate that Rp-cGMPS-BDB targets favorably the cGMP binding site consistent with a docking model of PDE3A-Rp-cGMPS-BDB active site. We conclude that Rp-cGMPS-BDB is an effective active site-directed affinity label for PDE3A with potential for other cGMP-dependent enzymes. |
| |
Keywords: | Affinity label Rp-cGMPS-BDB Human platelets Phosphodiesterase PDE3A |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|